A newly established clinical trial in the United Kingdom has set age 11 as the minimum enrollment threshold for children participating in puberty blocker research. This regulatory decision reflects current standards for developmental capacity assessment in pediatric hormone research and informed assent protocols.
The age benchmark emerged from rigorous evaluation of cognitive development milestones and research ethics principles. Across major healthcare systems, minimum enrollment ages vary considerably—the UK trial’s threshold represents one of the more conservative approaches to pediatric research inclusion in gender-affirming care.
Setting clear age-based eligibility criteria serves dual purposes: protecting research participants’ rights while ensuring adequate sample diversity for clinically meaningful outcomes. This data point underscores the ongoing evolution of regulatory frameworks governing pediatric hormone research. Read the full article on GMJ Newsroom.
Was this article helpful?
